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OBJECTIVES We sought to determine whether a multidisciplinary outpatient management program
decreases chronic heart failure (CHF) hospital readmissions and mortality over a six-month
period.
BACKGROUND Hospital admission for CHF is an important problem amenable to improved outpatient
management.
METHODS Two hundred patients hospitalized with CHF at increased risk of hospital readmission were
randomized to a multidisciplinary program or usual care. A study cardiologist and a CHF
nurse evaluated each patient and made recommendations to the patient’s primary physician
before randomization. The intervention team consisted of a cardiologist, a CHF nurse, a
telephone nurse coordinator and the patient’s primary physician. Contact with the patient was
on a prespecified schedule. The CHF nurse followed an algorithm to adjust medications.
Patients in the nonintervention group were followed as usual. The primary outcome was the
composite of the number of CHF hospital admissions and deaths over six months, compared
by using a log transformation t test by intention-to-treat analysis.
RESULTS The median age of the study patients was 63.5 years, and 39.5% were women. There were 43
CHF hospital admissions and 7 deaths in the intervention group, as compared with 59 CHF
hospital admissions and 13 deaths in the nonintervention group (p  0.09). The quality-of-
life score, percentage of patients on target vasodilator therapy and percentage of patients
compliant with diet recommendations were significantly better in the intervention group.
Cost per patient, in 1998 U.S. dollars, was similar in both groups.
CONCLUSIONS This study demonstrates that a six-month, multidisciplinary approach to CHF management
can improve important clinical outcomes at a similar cost in recently hospitalized high-risk
patients with CHF. (J Am Coll Cardiol 2002;39:471–80) © 2002 by the American College
of Cardiology
Improving the outpatient management of patients with
chronic heart failure (CHF) is an important challenge. The
majority of patients with CHF do not receive or comply
with optimal pharmacologic, dietary or physical activity
regimens (1–7). Elderly patients with CHF may benefit
from a focused multidisciplinary management approach
designed to improve treatment, patient compliance and
outcomes (8,9). We conducted a randomized clinical trial to
determine whether a program designed to implement opti-
mal medical therapy, increase patient understanding and
compliance and reduce financial barriers to care, coupled
with frequent telephone monitoring and clinic follow-up,
could decrease deaths and hospital readmissions, as well as
improve compliance and quality of life, at no extra cost in
patients with CHF at increased risk of early hospital
readmission.
METHODS
Study design. This was a prospective, randomized trial
performed at The Johns Hopkins Hospital and The Johns
Hopkins Bayview Medical Center. The Maryland Medical
Research Institute independently collected and analyzed all
data. An independent Oversight, Data, Safety and Moni-
toring Committee reviewed the protocol before the begin-
ning of the study, monitored the progress of the study and
assessed the occurrence of adverse events by treatment
group. The Joint Committee on Clinical Investigation at
The Johns Hopkins Medical Institutions approved the
study, and each patient provided written, informed consent
before randomization.
Eligibility of patients. English-speaking patients admitted
with a primary diagnosis of New York Heart Association
(NYHA) functional class III/IV CHF and judged to be at
high risk of CHF readmission were eligible for study
participation. At randomization, patients were usually no
From the *Division of Cardiology, Department of Medicine, The Johns Hopkins
University School of Medicine and the †Maryland Medical Research Institute,
Baltimore, Maryland. Partial funding was provided by CardioContinuum, Inc.,
Rockville, Maryland. Under a licensing agreement between The Johns Hopkins
University and CardioContinuum, the University and, in particular, its Division of
Cardiology, are entitled to royalty on the use of the CHF management program
described in this study. The University also owns CardioContinuum stock, which is
subject to certain restrictions under University policy. The University, in accordance
with its conflict of interest policies, is managing the terms of this arrangement. None
of the investigators, with the exception of Ms. Van Anden (once an employee of
CardioContinuum), have personal stock, royalty interests or consulting arrangements
with CardioContinuum.
Manuscript received June 14, 2001; revised manuscript received October 10, 2001,
accepted October 31, 2001.
Journal of the American College of Cardiology Vol. 39, No. 3, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01761-2
longer in NYHA functional class III/IV (Table 1). High
risk of hospital readmission was defined by the presence of
one or more of the following criteria, selected from the
literature (4–7,10–13) and from our clinical experience: age
70 years, left ventricular ejection fraction (LVEF) 35%,
at least one additional CHF hospital admission in the
previous year, ischemic cardiomyopathy, peripheral edema
at hospital discharge, 3 kg weight loss while in the
hospital, peripheral vascular disease or hemodynamic find-
ings (during the index admission) of pulmonary capillary
wedge pressure 25 mm Hg, cardiac index 2.0 l/min/m2,
systolic blood pressure 180 mm Hg or diastolic blood
pressure 100 mm Hg. Patients were ineligible if they had
any of the following: valvular heart disease requiring surgical
correction, active substance abuse, peripartum cardiomyop-
athy, hypertrophic cardiomyopathy with left ventricular
(LV) outflow tract obstruction, restrictive cardiomyopathy,
constrictive pericarditis, psychiatric disease or dementia
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  chronic heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
Table 1. Baseline Characteristics
Intervention Group
(n  102)
Nonintervention
Group (n  98)
Demographic data
Age (yrs) 60.2  13.8 (25–87) 63.7  15.0 (26–88)
Males 66 (64.7%) 55 (56.1%)
African American 34 (33.3%) 35 (35.7%)
White 65 (63.7%) 63 (64.3%)
Specialty of primary care physician
Internal medicine 67 (65.7%) 71 (72.5%)
Cardiology 30 (29.4%) 25 (25.5%)
Baseline medical data
Hypertension 68 (66.7%) 66 (67.3%)
Diabetes mellitus 40 (39.2%) 40 (40.8%)
LVEF 45% 89 (87.3%) 86 (87.8%)
Ischemic etiology 49 (48.0%) 49 (50.5%)
NYHA functional class
II 38 (37.3%) 33 (33.7%)
III 57 (55.9%) 60 (61.2%)
Medications
ACE inhibitor 92 (90.2%) 80 (81.6%)
Angiotensin II blocker 7 (6.9%) 10 (10.3%)
Beta-blocker 39 (38.2%) 39 (39.8%)
Digoxin 72 (70.6%) 64 (65.3%)
Diuretic 98 (96.1%) 96 (98.0%)
Hydralazine 4 (3.9%) 7 (7.2%)
Long-acting nitrate 14 (13.7%) 24 (24.5%)
Physical examination
Pulse (beats/min) 82.5  14.5 (47–112) 79.7  14.6 (52–129)
BP (mm Hg)
Systolic 118.0  21.3 (79–188) 120.2  20.7 (81–170)
Diastolic 69.0  12.2 (42–100) 68.4  10.9 (48–100)
Laboratory data
LVEF (%) 27.1  13.8 (10–70) 27.5  13.9 (5–60)
Creatinine (mg/dl) 1.3  0.5 (0.4–2.8) 1.3  0.5 (0.5–2.9)
Sodium (mmol/l) 137.0  3.9 (122–147) 137.1  3.6 (127–146)
Quality-of-life scores
Minnesota Living With
Heart Failure Questionnaire
Total 64.3, 68.5 (51–79) 62.4, 65.5 (52–78)
Physical 30.2, 34 (26–38) 30.6, 35 (27–38)
Emotional 14.6, 15 (9–21) 13.9, 16 (8–20)
Duke Activity Status
Score 5.5, 5 (3–7) 5.0, 4.5 (3–7)
Index 20.0, 17 (7–29) 17.0, 13 (7–24)
Data are presented as the mean value  SD (range; for age, physical examination and laboratory data), number (%) of
patients or mean and median values (25th to 75th percentile; for quality-of-life scores). There were no statistically significant
differences.
ACE  angiotensin-converting enzyme inhibitor; BP  blood pressure; NYHA  New York Heart Association.
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likely to limit compliance, concurrent noncardiac illness
likely to cause repeat hospital admissions, heart transplan-
tation likely to occur within six months, uncorrected thyroid
disease, serum creatinine 265 mol/l (3.0 mg/dl), long-
term intravenous inotropic therapy at home, cardiac surgery
or myocardial infarction during the index admission, active
participation in another research trial or unwillingness to
provide informed consent. Residence in a nursing home,
rehabilitation facility or outside the area served by the
clinical sites was also an exclusion criterion. After permis-
sion from the patient’s primary physician, patients were
approached at the end of the index hospital period.
Baseline evaluation. Baseline evaluation included a history
and physical examination performed by cardiologists spe-
cialized in the management of heart failure. Echocardiog-
raphy was performed to document LV function if it had not
been performed in the previous six months. Recommenda-
tions, including those regarding medication, diet and exer-
cise management, were documented in the patient’s medical
record before randomization.
Treatment assignment. The coordinating center made
treatment assignments by using an automated telephone
response system, after the baseline evaluation and recom-
mendations were recorded in the patients’ chart. Random
number schedules were prepared before initiation of patient
recruitment and were unknown to the clinical investigators.
Randomization was stratified by site and by the presence of
LV systolic dysfunction, defined by LVEF 45%.
Intervention group. The four members of the intervention
team were the telephone nurse coordinator, the CHF nurse,
the CHF cardiologist and the patient’s primary physician.
The telephone nurse coordinator made follow-up calls to
patients from a central site located in Rockville, Maryland.
Telephone calls were placed within 72 h of hospital dis-
charge, then weekly for one month—twice in the second
month and monthly thereafter, unless a problem occurred
that required more frequent contact. The telephone nurse
coordinator followed a set script and pursued problems as
clinically indicated, but did not adjust medications over the
telephone.
The CHF nurses were assigned to assist the intervention
group and helped to implement the therapeutic plan de-
signed by the CHF cardiologists. Patients had at least
monthly follow-up with these nurses. Most visits occurred
in CHF clinics located at each site, but some occurred in the
patient’s home. The CHF nurses adjusted medications
under the directions of the CHF cardiologists, following a
prespecified algorithm, which included initiation and titra-
tion of angiotensin-converting enzyme (ACE) inhibitors,
beta-blockers and diuretics. The algorithm included a 2-g
sodium-restricted diet, as well as a recommendation to
exercise by walking for 20 min at least four days per week.
The treatment plan was individualized for each patient. In
the course of the study, the algorithm was updated to
include, for example, the use of beta-blockers. All members
of the team, except for the patients’ primary physicians,
participated in weekly patient care meetings.
The CHF cardiologists designed and documented a
treatment plan for all study patients before randomization
and saw the patients at baseline and six months. They
designed the prespecified algorithm according to available
CHF guidelines and clinical experience.
The primary physicians approved of their patients’ par-
ticipation, as well as medication, dietary, activity and
follow-up regimens. They managed all problems not related
to CHF, received regular updates from the CHF nurses and
were notified of abnormal laboratory values. Most of the
primary physicians were internists (Table 1).
Patients in the intervention group with limited financial
resources were provided, if needed, a scale, a 3-g sodium
“Meals on Wheels” diet, medications, transportation to the
clinic and a telephone. All patients in the intervention group
were supplied with a pill sorter, a list of correct medications,
a list of dietary and physical activity recommendations, a
contact number available 24 h/day and patient education
material. The intervention continued for six months.
Nonintervention group. Patients assigned to the nonin-
tervention group were cared for by their primary physicians.
The baseline therapeutic plan designed by the CHF cardi-
ologist was documented in the patient’s chart, without
further intervention.
Outcome collection. No patient withdrew from the study.
Follow-up data were collected on every patient. Transplan-
tation was performed in two patients during the six-month
study period, and another had a prolonged pretransplant
hospital stay during the study period and underwent suc-
cessful transplantation shortly thereafter. Outcome data
were obtained at the six-month visit, and the patients were
then followed for an additional three months. The CHF
cardiologist, along with the CHF nurse, saw all patients
during the six-month visit.
Several methods were used to obtain complete ascertain-
ment of study outcomes. The importance of reporting all
hospital admissions was explained to each patient; patients
were asked to keep a diary of all hospital admissions, and the
diaries were sent to the coordinating center monthly. An
independent central telephone data collector, who had no
knowledge of the patients’ treatment assignment, collected
data monthly from all patients during the nine months after
enrollment. Medical document coordinators blinded to
treatment assignment searched the on-line medical records
of The Johns Hopkins Hospital and The Johns Hopkins
Bayview Medical Center for admissions during the study
period. If a hospital admission was found at another
hospital, medical document collectors searched that hospi-
tal’s medical records for additional admissions during the
study period.
The diaries, telephone interviews and medical records
were used to enumerate all hospital admissions and deaths.
Medical document collectors obtained copies or abstracts of
the medical records. The coordinating center deleted from
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all documents and records information that revealed per-
sonal identity or treatment assignment.
Outcomes. A committee composed of three cardiologists,
who had no knowledge of the treatment assignment, cate-
gorized each hospital admission and death using documents
prepared by the coordinating center. Two members inde-
pendently evaluated all cases. In the event of a discrepant
classification, the third member reviewed the report and
assigned the final classification.
The primary outcome variable was the composite of death
from any cause and the total number of CHF hospital
admissions. Planned secondary outcome variables included
death, CHF hospital admissions, total hospital admissions,
changes in quality of life (measured by the Minnesota
Living With Heart Failure Questionnaire [14]) and activity
status (measured by the Duke Activity Status Index [15]).
The best score on the Minnesota Living With Heart Failure
Questionnaire is 0 and the worst is 105. The best score on
the Duke Activity Status is 12 and the worst is 0. Similarly,
the weighted best score on the Duke Activity Status Index
is 58.2. The questionnaires were completed by the patients
and analyzed by the coordinating center in a blinded
fashion. Additional secondary end points assessed by the
CHF nurse included NYHA functional class, the patient’s
global assessment of how he or she felt and the amount of
ankle edema.
Planned secondary outcomes also included several indexes
of the quality of care, such as the percentage of patients with
systolic dysfunction who were receiving target vasodilators,
defined as ACE inhibitor therapy according to published
guidelines (16,17), or, if intolerant of ACE inhibitor ther-
apy, those taking either losartan (50 mg/day) or a combi-
nation of isosorbide dinitrate (up to 160 mg/day) and
hydralazine (up to 300 mg/day). Target beta-blocker doses
were not defined in the initial protocol, because at that time,
no beta-blockers were approved by the U.S. Food and Drug
Administration for use in patients with CHF. Additional
planned analyses included the degree of compliance with
dietary recommendations, as well as the percentage of
patients who were euvolemic according to the goal weight.
Goal weight was defined as that weight at which the jugular
venous pressure was 8 cm of water above the right atrium,
with a stable serum creatinine value 221 mol/l
(2.5 mg/dl) in the absence of ankle edema and symptomatic
orthostasis. The goal weight, assessed by the CHF nurse,
could be adjusted depending on the patient’s clinical con-
dition. Compliance with dietary recommendations was
assessed using a locally developed dietary sodium score,
which was completed by the patient at baseline and at the
final visit.
The cost of the personnel included direct and indirect
components. Salaries are consistent with those in the
published data and with average salaries in the mid-Atlantic
region (18–20). Salaries were adjusted for the recorded
actual time spent caring for the patients in the intervention
group and supervising the CHF nurse over the 2.5 years
required to complete the study for the nurses and physicians,
respectively. Pharmacy cost included all outpatient medica-
tions recorded during the study period, using wholesale,
generic outpatient drug costs taken from the Drug Topics
Red Book, 1997 to 1999 (21–23). Supplies included scales,
3-g sodium “Meals on Wheels” diet, medications, transpor-
tation to the clinic, pill sorters and telephones. Inpatient
costs (excluding professional fees) for readmission to the
two primary hospitals were measured in constant 1998 U.S.
dollars by applying state-regulatory cost-to-charge ratios
and annual inflation factors to actual charges. Costs for
inpatient stays at other hospitals were imputed by multiply-
ing the mean daily cost at the two primary hospitals by the
length of stay at other hospitals. Inpatient costs and length
of stay do not include two patients who underwent heart
transplantation and one patient who had a prolonged
pretransplant hospital stay during the six-month study
period; these patients were randomized to the intervention
group.
Statistical methods. Patient characteristics are presented
as counts and percentages and were compared using tests of
difference for two proportions for dichotomous data (24)
and the Mantel-Haenszel method (25) for data in multiple
categories. The Fisher exact test was used for characteristics
with a prevalence 5% (26). Survival and survival-free of
hospital admission were compared according to the Kaplan-
Meier method (27), using the log-rank test for statistical
inference (28).
Data measured on continuous scales were compared using
the t test (29) and the Wilcoxon rank-sum statistic (30).
Because cost and length of stay inherently have a severely
skewed distribution, with a median value of 0, these data
were expressed in percentiles and analyzed with the two-
tailed nonparametric Wilcoxon test. The Duke Activity
Index and Minnesota Living With Heart Failure scores
were analyzed using both unweighted and published
weighting methods.
The primary outcome, the combination of deaths and
the total number of CHF admissions, was analyzed using a
log transformation of counts of the primary outcome per
patient (0.5 was added to the count of the primary outcome
to accommodate patients with no hospital admissions in
the analysis, and death was counted as an event), and
comparisons were made by using the t test. A Poisson model
comparison (29) was also performed, as suggested by a
statistician of the Oversight, Data and Safety Monitoring
Committee at their initial meeting before patient enroll-
ment. Analyses were based on the intention-to-treat prin-
ciple.
The planned sample size was 100 patients per treatment
group, based on an alpha value of 0.05 and a power of 80%
for alternative hypotheses of a 35% relative reduction in the
primary outcome. One interim analysis was planned, setting
the critical value at p  0.001 and adjusting the final,
primary-analysis critical value at p  0.0487. For secondary
analyses in which 40% to 50% of patients had the outcome
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of interest and alpha  0.01, the estimated power was 80%
for relative reductions in the range of 37.5% to 50%.
RESULTS
Patients. From December 1996 until December 1998, 200
patients were enrolled in the study. There were 104 patients
randomized at The Johns Hopkins Hospital and 96 at The
Johns Hopkins Bayview Medical Center. There were 1,252
patients screened and found to be ineligible. Of these, 476
(36.6%) did not have NYHA functional class III/IV CHF
on admission or did not meet the high-risk inclusion
criteria. In addition, there were 776 high-risk patients
admitted with NYHA functional class III/IV CHF who
had one or more of the exclusion criteria. The causes of
exclusion include renal dysfunction (14.3%), dementia or
substance abuse (10.7%) and planned cardiac revasculariza-
tion or heart transplantation (10.2%), and 10.2% had
cardiac exclusions such as hypertrophic cardiomyopathy,
restrictive cardiomyopathy, amyloidosis and valvular heart
disease. Of excluded patients, 15.5% were participating in
another research protocol, 7% lived beyond our area and
5.1% lived in a nursing home or were discharged on an
intravenous inotrope. A variety of noncardiac disorders
thought likely to cause repeated hospital admissions led to
the exclusion of 12.8% of the patients. Finally, 11.9% of the
patients refused to participate, and 2.3% were excluded
because their primary-care physicians declined to partici-
pate.
The demographic and clinical characteristics of the two
randomized groups were statistically similar at baseline
(Table 1). The median age of the patients was 63.5 years
(range 25 to 88). The Minnesota Living With Heart Failure
and the Duke Activity Status Index scores are consistent
with a moderate impairment in quality of life and functional
capacity, respectively. At randomization, 94% of the pa-
tients were in NYHA functional class II/III.
Hospital admission and mortality. Thirteen patients in
the nonintervention group and seven in the intervention
group died during the six-month study period. There were
59 hospital admissions for CHF among 35 patients in the
nonintervention group, and 43 hospital admissions among
26 patients in the intervention group (p  0.09 by the
log-transformation t test and p  0.03 by Poisson model
comparison). There were fewer hospital admissions for any
reason in the intervention group, as well (Table 2). Treat-
ment effects were most marked after the third month, and
the event rates continue to separate through six months
(Fig. 1). A continued separation of the event rates in the two
groups was not seen in the three months after the end of the
intervention.
Baseline predictors of the primary end point on univariate
analysis were diabetes (p  0.003) and an ischemic cause of
CHF (p  0.001). Atrial fibrillation, LVEF 45%, the
presence of an internal cardioverter-defibrillator, age 65
years, NYHA functional class III at discharge from the
index hospitalization and a Minnesota Living With Heart
Failure total score 65 were not predictive of the primary
end point on univariate analysis.
Quality of care. The telephone nurse coordinator made
973 calls to patients in the intervention group, averaging 9.5
calls per patient. The CHF nurses made 862 patient visits,
or 8.5 visits per patient. The mean (SD) duration of a
Table 2. Events Within Six Months of Study Entry
Intervention
Group
(n  102)
Nonintervention
Group
(n  98) p Value
Death (life-table rate) 7 (6.9%) 13 (13.4%) 0.14 (LR)
Distribution of CHF hospital admissions or death
0 72 (70.6%) 58 (59.2%)
1 20 (19.6%) 26 (26.5%)
2 6 (5.9%) 6 (6.1%)
3 1 (1.0%) 2 (2.0%)
4 1 (1.0%) 3 (3.1%)
5 1 (1.0%) 2 (2.0%)
6 1 (1.0%) 1 (1.0%)
Mean 0.5 0.7
Total 50 72 0.09 (L), 0.03 (P)
Distribution of hospital admissions or death
0 55 (53.9%) 43 (43.9%)
1 26 (25.5%) 32 (32.7%)
2 13 (12.7%) 8 (8.2%)
3 4 (3.9%) 5 (5.1%)
4 1 (1.0%) 6 (6.1%)
5 2 (2.0%) 2 (2.0%)
6 1 (1.0%) 2 (2.0%)
Mean 0.8 1.1
Total 84 109 0.13 (L), 0.04 (P)
Data are presented as the number (%) of patients.
CHF  chronic heart failure; L  log transformation t test; LR  log-rank test; P  Poisson model comparison.
475JACC Vol. 39, No. 3, 2002 Kasper et al.
February 6, 2002:471–80 Multidisciplinary Care in High-Risk Outpatients With CHF
telephone call was 16  9 min, whereas the average length
of a visit by a CHF nurse was 57  21 min. The average
visit with the CHF cardiologist lasted 22  12 min in both
the intervention and nonintervention groups.
After six months, patients with systolic dysfunction in the
intervention group were more likely to be prescribed target
doses of vasodilators (74 of 80 patients vs. 43 of 71 patients
in the nonintervention group, p  0.001). Similarly, dietary
compliance was more likely to be described as “good” or
“average” in patients in the intervention group versus the
nonintervention group, based on a review of dietary history
(65 of 94 patients vs. 38 of 85 patients, p  0.002). The
intervention patients were also more likely to be at their goal
weight, as compared with the nonintervention patients (47
of 94 patients vs. 17 of 85 patients, p  0.001). There was
no difference in medication compliance.
Quality of life. At the final visit, patients in the interven-
tion group were less symptomatic, according to NYHA
functional class (Table 3). Patients in the intervention group
were more likely to report stable or improved symptoms, as
compared with those in the nonintervention group (81of 94
patients vs. 55 of 85 patients, p 0.003) and were less likely
to have ankle edema (18 of 89 patients vs. 35 of 85 patients,
p  0.003). Quality of life, measured by the Minnesota
Living With Heart Failure Questionnaire, improved in both
groups, but patients in the intervention group improved
more (Table 3). Improvement occurred in total score as well
as in both physical and emotional dimensions.
Cost. The most costly component of the intervention was
personnel (Table 4). The intervention, including salaries
and supplies, cost $904 per patient in the intervention
group. The mean outpatient pharmacy cost per patient was
similar in both groups: $1,353 in the intervention group and
$1,405 in the nonintervention group. The median number
of outpatient physician visits was four in both groups. The
greatest overall cost was readmission (Table 4). The costs of
readmission are consistent with the published costs of
admission due to CHF, which range from $4,397 to
$10,148 (31–35). Inpatient costs for all study patients
ranged from $0 to $239,760 (mean $10,085), and the length
of stay ranged from 0 to 132 days (mean 5.5). There was no
significant difference in inpatient or outpatient resource use
between the intervention and nonintervention groups
(Table 4).
In the analysis of cost, we excluded two patients who
underwent transplantation during the study and one who
did shortly thereafter. The first two were patients with the
highest and third highest inpatient costs. The third patient
had a relatively low inpatient cost. All were randomized to
the intervention group. If included, the mean length of stay
Figure 1. Life-table first event rates for death or readmission for chronic heart failure. The trial end point was 180 days or six months (p 0.12 by log-rank).
This was not the primary end point, which was death or all readmissions for chronic heart failure.
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in the intervention group increased to 8.7 days (75th
percentile, 4 days), and the mean inpatient cost increased to
$16,182 (75th percentile, $6,527). However, there remains
no significant difference in inpatient or outpatient resource
use between the intervention and nonintervention groups.
DISCUSSION
Readmission for CHF. Heart failure is common and
associated with high mortality and morbidity. Hospital
admission for CHF is frequent, and readmission rates of up
to 44% within six months are reported (10). Treatment
regimens for CHF are increasingly complex and require
considerable expertise and time on the part of physicians,
who are usually not heart failure experts. Numerous studies
indicate that factors related to patient behavior account for
large numbers of hospital admissions (4–7,36). Other bar-
riers to effective CHF management include a lack of
coordination among various providers and the cost of
medications and special diets.
The intervention. The program we describe was designed
to overcome the aforementioned barriers to improved out-
patient CHF management. A 55-page CHF algorithm,
Table 3. Clinical Data at Six-Month Final Visit
Intervention
Group
(n  102)
Nonintervention
Group
(n  98)
p
Value
Data available 94 85
NYHA functional class
I 7 (8%) 9 (11%)
II 62 (67%) 34 (40%)
III 18 (20%) 35 (41%)
IV 5 (5%) 7 (8%) 0.03 (CMH)
Missing 2 (2%) 0
Patient-assessed CHF symptoms
Stable 41 (44%) 29 (35%)
Improved 40 (43%) 26 (31%)
Worse 11 (12%) 29 (35%) 0.003
Missing 2 (2%) 1 (1%)
Ankle edema 18/89 (20%) 35 (41%) 0.003
At goal weight 47 (50%) 17 (20%) 0.001
Diet compliance
Good 32 (34%) 12 (14%)
Average 33 (35%) 26 (31%)
Poor 25 (27%) 44 (52%) 0.002
Missing 4 (4%) 3 (4%)
Medications
ACE inhibitor 78 (82.9%) 60 (70.6%) 0.07
Angiotensin II blocker 12 (12.8%) 7 (8.2%) 0.33
Beta-blocker 43 (45.7%) 32 (37.6%) 0.27
Digoxin 67 (71.3%) 51 (60.0%) 0.11
Diuretic 87 (92.6%) 75 (88.2%) 0.32
Hydralazine 5 (5.3%) 7 (8.2%) 0.44
Long-acting nitrate 14 (14.9%) 17 (20.0%) 0.37
Quality-of-life scores
Minnesota Living With Heart
Failure Questionnaire
At final visit
Total 35.7, 33 (14–52) 45.3, 51 (22–64) 0.01 (W)
Physical 14.7, 14 (5–21) 21.3, 25 (11–32) 0.0006 (W)
Emotional 9.0, 6 (2–15) 10.6, 10 (2–19) 0.33 (W)
Change from baseline
Total 28.3, 28 15.7, 15 0.001 (W)
Physical 15.4, 17 8.7, 8 0.0004 (W)
Emotional 5.3, 4 2.5, 1 0.03 (W)
Duke Activity Status
At final visit
Score 6.8, 6 (5–9) 6.0, 6 (4–8) 0.05 (W)
Index 25.7, 21 (15–37) 21.8, 19 (10–31) 0.04 (W)
Change from baseline
Score 1.1, 1 0.8, 1 0.44 (W)
Index 5.5, 4.5 3.9, 2.7 0.52 (W)
Data are presented as the number (%) of patients or mean and median values (25th to 75th percentile).
CMH  Cochran-Mantel-Haenszel test for trend; W  Wilcoxon test; other abbreviations as in Tables 1 and 2.
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incorporating detailed descriptions of the initiation, titra-
tion and monitoring of medical, dietary and activity thera-
pies, formed the basis for recommendations provided by the
multidisciplinary team. The CHF algorithm was based on
randomized clinical trials, published guidelines and our
personal expertise and experience. The algorithm provided
“guardrails to practice decisions” (37), but did not provide a
protocol of a common standard therapy for patients with
CHF.
In our study, CHF experts were available to provide
guidance, but did not see the patients between the initial
and final visits. Nurses supervised by cardiologists, along
with primary-care physicians, provided most of the care,
adjusted medications and provided dietary and physical
activity guidance. It is important to note that primary-care
physicians were not excluded from CHF disease manage-
ment, but rather were integrated into the team care of their
patients.
Primary end point analysis. The multidisciplinary ap-
proach is associated with a clinically important decline in
death or CHF hospital admissions over the six-month
intervention period (p  NS). The primary end point of
death plus hospital admissions for CHF was chosen because
patients may have multiple admissions for CHF, all of
which are important to prevent. The data were also analyzed
in terms of the time to first event (Fig. 1), with similar
results. Differences in the primary outcome between the two
groups widened beginning in the third month. During the
three months after termination of the intervention, the
curves no longer separate, suggesting that the intervention
should be continued. There were significant differences in
quality of life, assessed by the Minnesota Living With Heart
Failure Questionnaire, and quality of care, assessed by both
the proportion of patients on target vasodilator therapy and
the proportion of patients at their goal weight. Although the
primary outcome is of borderline statistical significance, an
overall view of the data suggests that the intervention was
beneficial.
Predictors of readmission or death. Only diabetes and an
ischemic cause of CHF independently predicted readmis-
sion for CHF or death—the primary end point. Both
diabetes and coronary disease are associated with a poor
prognosis (38–41).
Comparison with previous studies. Management pro-
grams for CHF have received wide acceptance, primarily on
the basis of uncontrolled studies. There are several random-
ized trials of disease management in patients with CHF and
two review articles (42,43). A recently published meta-
analysis of 11 randomized trials supports a reduction in
CHF hospital admissions for patients participating in some
programs (44). Of the randomized trials, there are two
assessing the effectiveness of interventions designed to
improve care delivery. At baseline, the patients in our trial
were younger, were more often male, had a lower average
LVEF and were less likely to have coronary disease, as
compared with the patients enrolled in the two most similar
randomized trials. To the best of our knowledge, this is both
the first multicenter trial of CHF disease management and
the first trial with active initiation and titration of medica-
tions by nurse practitioners.
Rich et al. (8) reported that intensive patient education,
coupled with three-month follow-up using home-care ser-
vices, improved hospital admission-free survival in patients
with a median age of 79 years. Our findings extend the
benefits of this approach to a longer intervention period and
to a younger population. We emphasized the involvement
of the patient’s primary physician, as well as active initiation
and titration of medications by nurses.
Stewart et al. (9) reported that a single visit by a cardiac
nurse 7 to 14 days after hospital discharge, followed by a
report to the patient’s physician, was associated with im-
proved survival, without unplanned hospital admission over
a six-month period in patients with CHF with a mean age
of 75 years. The only other contacts with the study team
were telephone calls at three and six months. Our interven-
tion program was different in that it included extensive
patient contact and education, intensive pharmacologic
intervention and involvement of the patient’s physician;
also, our patients were younger.
In our trial, the patient’s primary physician, regardless of
randomization, received expert recommendations at the
time of the patient’s enrollment. This is reflected by the
higher utilization of ACE inhibitors and beta-blockers at
baseline in our trial, as compared with the other two trials.
This may explain the lower event rate in the current trial and
why the differences between the two groups were most
apparent after the third month, whereas in both the Rich et
al. (8) and Stewart et al. (9) trials, the differences were
present almost immediately after randomization.
Cost. This was a relatively expensive program, although
the cost of the hospital period dwarfed the cost of the
program itself. There was no significant difference in re-
source use between the two groups (Table 4), but our
sample size was too small for reliable conclusions, especially
because overall resource use by patients with CHF is
sensitive to high-cost outliers. This is demonstrated in
Table 4. Resource Use Per Patient by Treatment Assignment in
Constant 1998 U.S. Dollars
Intervention
Group
Nonintervention
Group
Telephone coordinator $129 $0
CHF nurse $541 $0
CHF cardiologist $196 $0
Supplies $38 $0
Outpatient pharmacy (mean) $1,353 $1,405
Inpatient length of stay (days)*
Mean 6.3 4.8
75th percentile 3 7
Inpatient cost†
Mean $11,315 $8,789
75th percentile $5,952 $10,898
*p  0.17 and †p  0.20, favoring the intervention group.
CHF  chronic heart failure.
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Table 4 by the difference between the mean and 75th
percentile for both inpatient length of stay and inpatient
cost. Although there were fewer admissions in the interven-
tion group, the average admission was more expensive. This
suggests that the intervention decreases admission for rela-
tively less severe and hence less expensive problems.
Study limitations. Several limitations should be noted.
First, the program was multidisciplinary and not designed to
analyze the relative contributions of its various components.
Second, physicians caring for patients in the noninterven-
tion group received expert recommendations at the time
that their patients were discharged from the index hospital
period and knew their patients were in a randomized trial
assessing CHF treatment. Thus, the comparison was not to
a strict usual care group, and these factors may have
decreased the event rate in the nonintervention arm. Third,
some but not all of the secondary outcomes were collected in
an unblinded manner by the CHF nurse, and not all of the
tools utilized to assess medication and dietary compliance
have been validated. This may have introduced bias in those
unblinded secondary end points. Fourth, these results may
not be applicable to all patients with CHF, because we
specifically targeted patients thought to be at high risk of
readmission. Finally, it is likely that not all patients with
CHF require such an extensive intervention. We are unable
to determine, from our data, which patient subgroups
benefited from participation. Many commercial CHF man-
agement programs do not involve cardiologists or CHF
nurses, but rely only on telephone management. It is
unclear, from our data, whether telephone management
alone results in a benefit. A significant component of future
investigation will be to determine which patient subsets
benefit most from this intervention strategy.
Conclusions. Our results indicate that a multidisciplinary
approach to the management of high-risk outpatients with
CHF, utilizing an expert knowledge algorithm, frequent
monitoring, intensive and continuing patient education and
close interaction with the patient’s primary physician, im-
proves quality of life, with a trend toward improvement in
the primary end point of death and total number of CHF
hospital admissions over a six-month intervention period.
Future studies are needed to determine which physiologic
and behavioral characteristics best predict the need for
specific intervention strategies.
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